Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

STK295900, a dual inhibitor of topoisomerase 1 and 2, induces G(2) arrest in the absence of DNA damage.

Kim SO, Sakchaisri K, Thimmegowda NR, Soung NK, Jang JH, Kim YS, Lee KS, Kwon YT, Asami Y, Ahn JS, Erikson RL, Kim BY.

PLoS One. 2013;8(1):e53908. doi: 10.1371/journal.pone.0053908. Epub 2013 Jan 22. Erratum in: PLoS One. 2013;8(6): 10.1371/annotation/c5f432f6-1e92-42c0-8727-7ae972215d6f. N R, Thimmegowda [corrected to Thimmegowda, N R].

2.

Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.

Ahmad P, Woo H, Jun KY, Kadi AA, Abdel-Aziz HA, Kwon Y, Rahman AF.

Bioorg Med Chem. 2016 Apr 15;24(8):1898-908. doi: 10.1016/j.bmc.2016.03.017. Epub 2016 Mar 8.

PMID:
26988802
3.

Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.

Pan X, Hartley JM, Hartley JA, White KN, Wang Z, Bligh SW.

Phytomedicine. 2012 May 15;19(7):618-24. doi: 10.1016/j.phymed.2012.02.003. Epub 2012 Mar 6.

PMID:
22402246
4.

Complex response of breast epithelial cell lines to topoisomerase inhibitors.

Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR.

Anticancer Res. 1998 Jul-Aug;18(4C):2919-32.

PMID:
9713486
5.

Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.

Hofland K, Petersen BO, Falck J, Helin K, Jensen PB, Sehested M.

Clin Cancer Res. 2000 Apr;6(4):1488-97.

6.

HY-1 induces G(2)/M cell cycle arrest in human colon cancer cells through the ATR-Chk1-Cdc25C and Weel pathways.

Zhao Y, Wu Z, Zhang Y, Zhu L.

Cancer Sci. 2013 Aug;104(8):1062-6. doi: 10.1111/cas.12182. Epub 2013 May 15.

7.

TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II.

Barthelmes HU, Habermeyer M, Christensen MO, Mielke C, Interthal H, Pouliot JJ, Boege F, Marko D.

J Biol Chem. 2004 Dec 31;279(53):55618-25. Epub 2004 Oct 19.

8.

Antagonism between curcumin and the topoisomerase II inhibitor etoposide: a study of DNA damage, cell cycle regulation and death pathways.

Saleh EM, El-awady RA, Eissa NA, Abdel-Rahman WM.

Cancer Biol Ther. 2012 Sep;13(11):1058-71. doi: 10.4161/cbt.21078. Epub 2012 Aug 16.

9.

Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics.

Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y, Lin NH, Sham HL, Wang JY, Sowin TJ, Rosenberg SH, Zhang H.

Int J Cancer. 2006 Dec 15;119(12):2784-94.

10.

Biological characterization of MLN944: a potent DNA binding agent.

Sappal DS, McClendon AK, Fleming JA, Thoroddsen V, Connolly K, Reimer C, Blackman RK, Bulawa CE, Osheroff N, Charlton P, Rudolph-Owen LA.

Mol Cancer Ther. 2004 Jan;3(1):47-58.

12.

The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.

Thomas A, Perry T, Berhane S, Oldreive C, Zlatanou A, Williams LR, Weston VJ, Stankovic T, Kearns P, Pors K, Grand RJ, Stewart GS.

Oncogene. 2015 Jun;34(25):3336-48. doi: 10.1038/onc.2014.266. Epub 2014 Aug 18.

PMID:
25132271
13.
14.

Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.

Lelièvre S, Benchokroun Y, Larsen AK.

Mol Pharmacol. 1995 May;47(5):898-906.

PMID:
7746278
15.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
17.
18.

Unique biochemical, cytotoxic, and antitumor activity of camptothecin and 4beta-amino-4'-O-demethylepipodophyllotoxin conjugates.

Chang JY, Guo X, Chen HX, Jiang Z, Fu Q, Wang HK, Bastow KF, Zhu XK, Guan J, Lee KH, Cheng YC.

Biochem Pharmacol. 2000 Mar 1;59(5):497-508.

PMID:
10660116
19.

2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.

Dwarakanath BS, Khaitan D, Ravindranath T.

Cancer Biol Ther. 2004 Sep;3(9):864-70. Epub 2004 Sep 18.

PMID:
15254410
20.

A series of novel terpyridine-skeleton molecule derivants inhibit tumor growth and metastasis by targeting topoisomerases.

Kwon HB, Park C, Jeon KH, Lee E, Park SE, Jun KY, Kadayat TM, Thapa P, Karki R, Na Y, Park MS, Rho SB, Lee ES, Kwon Y.

J Med Chem. 2015 Feb 12;58(3):1100-22. doi: 10.1021/jm501023q. Epub 2015 Feb 2.

PMID:
25603122

Supplemental Content

Support Center